Cardiovascular outcomes, long-term efficacy and safety In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109]
Phase 2 trial data shows average weight loss of 24.2% at 48 weeks on the 12 mg dose, which translates to roughly 58 pounds for the average participant
The kit includes one 10mg vial of retatrutide in lyophilized form at 98% purity per supplier batch specification, with selected lots independently tested by Janoshik Analytical
The crux of the issue is that most people do not have the means, financially or logistically, to always eat a diverse, nutrient-dense, whole-foods based diet
Drst U., SGLT2-Hemmer in der Therapie, Teil 2Niereninsuffizienz, der informierte Arzt 11/2023:14-17 3
In an AD mouse model, GLP-1RAs were demonstrated to reduce the levels of AD pathological markers, including oligomeric antibodies and antibody plaque load, reduce the activation of microglia, and improve memory behavior (35, 44, 45)
